Prothena Co. PLC (NASDAQ:PRTA) Shares Purchased by Virtus ETF Advisers LLC
Virtus ETF Advisers LLC boosted its position in Prothena Co. PLC (NASDAQ:PRTA) by 23.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,379 shares of the biotechnology company’s stock after acquiring an additional 5,461 shares during the quarter. Virtus ETF Advisers LLC owned 0.07% of Prothena worth $300,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of PRTA. Dimensional Fund Advisors LP raised its holdings in Prothena by 34.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,272,832 shares of the biotechnology company’s stock valued at $13,110,000 after acquiring an additional 328,166 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Prothena by 309.5% in the first quarter. BNP Paribas Arbitrage SA now owns 11,061 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 8,360 shares during the last quarter. SG Americas Securities LLC purchased a new position in Prothena in the first quarter valued at approximately $114,000. Rhumbline Advisers increased its stake in Prothena by 11.3% in the first quarter. Rhumbline Advisers now owns 63,904 shares of the biotechnology company’s stock valued at $775,000 after purchasing an additional 6,488 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new position in Prothena in the first quarter valued at approximately $198,000. 96.83% of the stock is currently owned by hedge funds and other institutional investors.
Prothena stock traded down $0.30 during mid-day trading on Friday, hitting $8.42. The company had a trading volume of 150,968 shares, compared to its average volume of 206,828. The stock has a market cap of $368.24 million, a price-to-earnings ratio of -2.33 and a beta of 2.18. Prothena Co. PLC has a 1 year low of $6.71 and a 1 year high of $14.77. The company has a quick ratio of 14.95, a current ratio of 14.94 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average of $8.56 and a 200 day moving average of $10.33.
Several equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Wednesday, June 19th. ValuEngine upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Barclays reiterated a “sell” rating and issued a $9.00 price target on shares of Prothena in a research note on Friday, May 31st. Finally, BidaskClub lowered shares of Prothena from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $11.26.
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Further Reading: Sell-Side Analysts
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. PLC (NASDAQ:PRTA).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.